[Formula 1] Neurokinin antagonism activity, the present invention is substituted with 1 antagonism activity NK, 3 antagonism activity NK, 3 antagonism activity, combined NK 1 / NK 2 / NK 2 and antagonism activity combined NK 1 / NK especially diaza - - spiro - [5.5] - oxa was undecanone derivatives, their preparation, compositions comprising them, as well as a drug, in particular schizophrenia, emesis, anxiety and depression, irritable bowel syndrome ( IBS), circadian rhythm disorders, pre-eclampsia, nociception, pain, dysuria, for example, urinary incontinence, neuropathic pain and visceral, pancreatitis, neurogenic inflammation, asthma, chronic obstructive pulmonary disease, as well as (COPD), especially for the prevention and / or relates to the use and their treatment. Base addition salts or the pharmaceutically acceptable acid thereof, the stereochemically isomeric forms thereof, pro thereof and their N- oxide forms a compound represented by the general formula (I) according to the present invention and can It also comprise-drugs, all substituents are as defined in claim 1 herein.【化1】本発明は、ニューロキニン拮抗作用活性、特にNK1拮抗作用活性、NK3拮抗作用活性、組み合わせNK1/NK2拮抗作用活性および組み合わせNK1/NK2/NK3拮抗作用活性、を有する置換されたオキサ-ジアザ-スピロ-[5.5]-ウンデカノン誘導体、それらの製造、それらを含んでなる組成物、並びに薬品としての、特に統合失調症、嘔吐、不安症および鬱病、刺激性腸症候群(IBS)、日周期リズム障害、子癇前症、侵害受容、疼痛、特に内臓および神経障害疼痛、膵臓炎、神経性炎症、喘息、慢性閉塞性肺疾病(COPD)並びに排尿障害、例えば尿失禁、の処置および/または予防のための、それらの使用に関する。本発明に従う化合物は一般式(I)により表すことができそしてそれらの製薬学的に許容可能な酸または塩基付加塩類、それらの立体化学的異性体形態、それらのN-オキシド形態およびそれらのプロドラッグ類も含んでなり、ここで全ての置換基は請求項1の通りに定義される。
